Innoviva, INC. (INVA) — 10-Q Filings

10-Q Filings (6)

• Innoviva's Net Income Soars on Strong Product Sales, FDA Nod for Zoliflodacin — Nov 5, 2025 Risk: medium
  Innoviva, Inc. reported a significant increase in net income for the three and nine months ended September 30, 2025, reaching $89.908 million and $107.012 milli
• Innoviva's Q2 Earnings Soar on Strong Royalty Growth — Aug 6, 2025 Risk: medium
  Innoviva, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $68.5 million, up from $58.1 million in the prior-y
• Innoviva 10-Q: Convertible Notes Focus — May 7, 2025 Risk: medium
  Innoviva, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on its convertible notes.
• Innoviva, Inc. Files Q3 2024 10-Q Report — Nov 6, 2024 Risk: medium
  Innoviva, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and business operations, including information
• Innoviva Q2 2024 10-Q: Financials and Key Agreements — Jul 31, 2024 Risk: medium
  Innoviva, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance, including revenues and liabilities. Key fi
• Innoviva, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: low
  Innoviva, Inc. (INVA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Innoviva, Inc. filed a 10-Q report for the period ending March 31, 2024. The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX